GlaxoSmithKline

RockFlow TradeGPT

FDA Approves GSK's Ojjaara For Bone Marrow Cancer: A Game-Changer In The Market

Pleasant Surprise: FDA Approves GSK's Ojjaara (momelotinib) for bone marrow cancer treatment. GSK obtained it via Sierra Oncology deal, boosting their market position. This positive development suggests considering GSK stock purchase.